TMPRSS2 and prostate carcinoma: We finally evaluated our pPSS in the Tyrol cohort28,29, a prostate cancer (PCa) dataset including 1036 control samples and 837 cancer samples, of which 280 (of 492 with ERG gene status annotation) are annotated as PCa samples collected from patients overexpressing the ERG gene due to a TMPRSS2-ERG fusion (i.e., ERG subtype patients).